-
Jan 17, 2025 | 
onlinelibrary.wiley.com | Robert J. Mentz |Stefan Anker |Bertram Pitt |Peter Rossing
Supporting Information Filename Description ejhf3569-sup-0001-Supinfo.docxWord 2007 document , 620.3 KB Appendix S1. Supporting Information. References 1, , . Detecting and treating lung congestion with kidney failure. Clin J Am Soc Nephrol 2022; 17: 757–765. https://doi.org/10.2215/cjn.14591121 2, , , . Volume overload and adverse outcomes in chronic kidney disease: Clinical observational and animal studies. J Am Heart Assoc 2015; 4:e001918.
-
Oct 22, 2024 | 
onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Rebecca Young |Javed Butler
Introduction The vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial demonstrated a 10% relative and 4.2 events/100 patient-years absolute risk reduction in a composite of heart failure (HF) hospitalization (HFH) or cardiovascular death relative to placebo in patients with high-risk HF.1 Differences in patient risk profiles add complexity to comparing the relative efficacy of vericiguat with other approved contemporary HF therapies.2 Thus, we...
-
Oct 9, 2024 | 
onlinelibrary.wiley.com | João Sérgio Neves |Ana Rita Leite |Robert J. Mentz |Rury R Holman
Supporting Information Filename Description ejhf3478-sup-0001-Supinfo.docxWord 2007 document , 699.2 KB Appendix S1. Supporting Information. References 1, , , , , , et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653–662.
-
Sep 1, 2024 | 
jacc.org | Andrew P. Ambrosy |Orly Vardeny |Robert J. Mentz |Joycie Chang
AbstractThe pathophysiology of heart failure (HF) is related to the overactivation of the mineralocorticoid receptor (MR), leading to fluid retention and adverse myocardial remodeling.
-
Aug 14, 2024 | 
jamanetwork.com | Dalane W. Kitzman |Robert J. Mentz |Gregory Lewis |Robin Myte
Key PointsQuestion
What are the effects of verinurad, a novel urate transporter–1 inhibitor, on exercise capacity and symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and elevated serum uric acid (SUA) level?
-
May 15, 2024 | 
onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Robert M. Clare |Daniel Wojdyla
Supporting Information Filename Description ejhf3293-sup-0001-Supinfo.docxWord 2007 document , 215.2 KB Appendix S1. Supporting information. References 1, , , , , , et al.; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial. JAMA 2023; 329: 214–223. https://doi.org/10.1001/jama.2022.23924 2, , , , , , et al.
-
May 12, 2024 | 
jamanetwork.com | Senthil Selvaraj |Brian Claggett |Robert J. Mentz |Michel G. Khouri
Key PointsQuestion
What is the natural history and cardiovascular burden of the V142I variant of the transthyretin (TTR) gene among US Black carriers across mid to late life? Findings
Across 4 cohort studies, carriers (754/23 338) faced a substantially increased risk for heart failure (by age 63 years) and death (by age 72 years), similarly in men and women, which was estimated to contribute to approximately 1 million years of life lost among US Black individuals aged ≥50 years.
-
May 7, 2024 | 
onlinelibrary.wiley.com | Andrew Sherwood |James A. Blumenthal |Robert J. Mentz |Gary G. Koch
Introduction Elevated depressive symptoms have been found to be associated with a marked increase in adverse clinical outcomes for heart failure (HF) patients with reduced ejection fraction (HFrEF).1-3 The increased risk of adverse clinical outcomes associated with elevated depressive symptoms in HFrEF patients is substantial, even in the absence of levels that denote clinical depression.3-6 There is also evidence that depressive symptoms that increase or worsen over time may signal HF...
-
May 1, 2024 | 
jacc.org | Robert J. Mentz |Amanda Stebbins |Javed Butler |Chern-En Chiang
References1. "Clinical course of patients with worsening heart failure with reduced ejection fraction". J Am Coll Cardiol . 2019;73:935-944. 2. "Vericiguat in patients with heart failure and reduced ejection fraction". N Engl J Med . 2020;382:1883-1893. 3. "A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA Trial". J Am Coll Cardiol HF . 2018;6:96-104. 4.
-
Mar 29, 2024 | 
digitalcommons.library.tmc.edu | Rury R Holman |M Angelyn Bethel |Robert J. Mentz |Vivian P. Thompson
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.
